News

20/10/2004 - FDA grants orphan drug status to two new anticancer drugs.

The U.S. Food and Drug Administration (FDA) on October 6 and 7, 2004, granted orphan drug status to, respectively, Yondelis, a drug used to treat soft tissue sarcomas, and Aplidin, a drug for use in treating multiple myeloma. Both drugs were developed by Zeltia, the latter in partnership with Johnson & Johnson Pharmaceutical Research & Development. Aplidin had in June 2004 received FDA approval for use in treating acute lymphoblastic leukemia. Both drugs are currently in clinical trials.

News Archive

3/8/2001	WHY?
17/11/2001	W.H.O. Collaborating Centre for Cancer Control of Uncommon Tumours
10/12/2001	On November 30th, in the hall of the S. Pio X Private Hospital of Milan, Italy, the "Rare Tumor: actuality and projects" congress took place.
18/12/2001	Post-meeting survey
3/12/2002	QUIZ
5/5/2002	Dear Colleagues,
29/01/2003	New publication on rare cancers !
28/07/2003	Thyroid Cancer Treatment Receives Orphan Drug Status
02/08/2003	Breast cancer in men
24/09/2003	GISTs: The revolution continues
28/10/2003	Lessons learned from the management of a rare genetic cancer.
17/11/2003	Successful photodynamic therapy for nonresectable cholangiocarcinoma.
07/01/2004	Gene associated with higher risk of melanoma in men
08/03/2004	Susceptibility to Common Adult Cancers in Retinoblastoma Survivors
29/03/2004	FDA Approves First Drug for mesothelioma
25/08/2004	Gene therapy cures malignant melanoma in mice
15/11/2004	New experimental drug for myeloproliferative disorder
20/01/2005	New leukemia treatment granted FDA orphan drug status.
28/02/2005	U.S. F.D.A. grants new orphan drug designation for a targeted therapeutic for head and neck cancer.
02/05/2005	Possible targets for a multiple myeloma vaccine
17/10/2005	Orphan drug troxacitabine approved for AML in EU
03/11/2005	FDA designes interleukin 21 as an orphan drug
01/12/2005	Zactima has received FDA orphan drug designation
25/01/2006	CETT Program for Rare Genetic Diseases
23/02/2006	New research studies of multiple myeloma